What the FDA labels say about taking them together
Fostamatinib and rosuvastatin
Fostamatinib's FDA label of November 5, 2025 names rosuvastatin in its drug interactions section, and rosuvastatin's label names fostamatinib too. The rosuvastatin label: “Mechanism and Clinical Effect (s): Fostamatinib increased rosuvastatin exposure more than 2.0-fold.”
Check it at the source: the fostamatinib FDA label on DailyMed (effective November 5, 2025, Rigel Pharmaceuticals, Inc.); the rosuvastatin FDA label on DailyMed (effective September 4, 2026, ScieGen Pharmaceuticals, Inc.).
What does the fostamatinib label say about rosuvastatin?
Fostamatinib label, drug interactionsBCRP Substrates Concomitant use of TAVALISSE may increase concentrations of BCRP substrate drugs (e.g., rosuvastatin).
Source: FDA drug label (TAVALISSE), Rigel Pharmaceuticals, Inc., effective November 5, 2025 (SPL set 21149cc3-049b-43e2-b141-c9499160556c), via openFDA; the full label on DailyMed
What does the rosuvastatin label say about fostamatinib?
Rosuvastatin label, drug interactionsMechanism and Clinical Effect (s): Fostamatinib increased rosuvastatin exposure more than 2.0-fold.
Source: FDA drug label (Rosuvastatin), ScieGen Pharmaceuticals, Inc., effective September 4, 2026 (SPL set ee4933c5-0d97-494d-ac0f-2083e0100836), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Fostamatinib | Rosuvastatin | |
|---|---|---|
| Labeled for | n/a | Heart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke prevention |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $0.0692 per tablet 40 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once